September 19th 2024
The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine therapy and another CDK4/6 inhibitor.
September 16th 2024
September 15th 2024
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances...
October 10, 2024
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Disease Control Rate of 45% Achieved With Sacituzumab Govitecan in Heavily Pretreated TNBC
December 7th 2017An overall disease control rate of 45% was achieved with sacituzumab govitecan (IMMU-132) therapy in patients with heavily pretreated metastatic triple-negative breast cancer (mTNBC), according to updated findings of a study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).
Read More
Pembrolizumab/Trastuzumab Combo Generates Activity in Trastuzumab-Resistant Breast Cancer Subgroup
December 7th 2017In results from the phase Ib/II PANACEA trial presented at the 2017 San Antonio Breast Cancer Symposium (SABCS), the combination of pembrolizumab (Keytruda) and trastuzumab (Herceptin) achieved an objective response rate (ORR) of 15.2% in patients with trastuzumab-resistant, PD-L1–positive, HER2-positive breast cancer.
Read More
Sir Richard Peto Honored with SABCS's 2017 William L. McGuire Memorial Lecture Award
December 2nd 2017Sir Richard Peto, FRS, a recognized pioneer in epidemiology and health statisticians, will be honored with the William L. McGuire Memorial Lecture Award at the 2017 San Antonio Breast Cancer Symposium (SABCS), to be held December 5 to 9 in San Antonio, Texas. The topic of his award lecture will be announced at a later date, according to a press release from SABCS.
Read More
Ramon Parsons Awarded Outstanding Investigator Award from The National Cancer Institute
November 29th 2017Renowned scientist Ramon Parsons, MD, PhD, has been awarded an Outstanding Investigator Award (OIA) from the National Cancer Institute. The award guarantees $6.7 million for 7 years of research into the tumor-suppressing functions of the <em>PTEN</em> gene, which he discovered.
Read More
Expert Discusses Impact of Genetic Testing in Breast Cancer
November 29th 2017Laura J. van’t Veer, PhD, discusses determining more accurate methods of treatment for patients with early- and late-stage breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.
Read More
New Treatment Options Emerging for Patients With HER2+ Breast Cancer
November 29th 2017Lajos Pusztai, MD, discusses neoadjuvant and adjuvant treatment decisions for patients with HER2-positive breast cancer, as well as the potential of immunotherapy in the metastatic setting.<br />
Read More
Ovarian Suppression and Bone Management in Breast Cancer
November 29th 2017Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses ovarian suppression and bone cancer management in breast cancer.
Watch
Ribociclib Meets Primary Endpoint of PFS for HR+/HER2- Breast Cancer
November 27th 2017Ribociclib (Kisqali) met its primary endpoint for progression-free survival (PFS) in premenopausal women with hormone-receptor (HR)–positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer, according to topline results from the MONALEESA-7 trial, Novartis recently announced in a press release.
Read More
Latest Advances in the Development of CDK4/6 Inhibitors in HR+ Breast Cancer
November 27th 2017Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses advances in the development of CDK4/6 inhibitors for the treatment of hormone receptor (HR)-positive breast cancer.
Watch
Fulvestrant/Abemaciclib Combo Receives FDA Approval for HR+/HER2- Breast Cancer
November 16th 2017Fulvestrant (Faslodex) has been approved by the FDA for use in combination with the CDK4/6 inhibitor abemaciclib (Verzenio) as a treatment for patients with HR+/HER2- advanced or metastatic breast cancer who have progressed after endocrine therapy.
Read More
Study Shows AKT1 E17K a Targetable Mutation Through AKT Inhibition Across Various Cancer Types
November 7th 2017Amultihistology basket study proved the targetability of the <em>AKT1 E17K</em> mutation in human cancers by treating patients with various types of cancer harboring an <em>AKT1 E17K </em>mutation with AZD5363, an oral pan-AKT inhibitor, according to findings published in the <em>Journal of Clinical Oncology</em>.
Read More
Olaparib Granted FDA's Priority Review for BRCA+ Breast Cancer
October 20th 2017A supplemental New Drug Application for olaparib (Lynparza) has been granted a priority review by the FDA for the treatment of patients with germline <em>BRCA</em>-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic settings, AstraZeneca and Merck, the co-developers of the PARP inhibitor, recently announced.
Read More
Frontline Abemaciclib Receives FDA's Priority Review for HR+/HER2- Advanced Breast Cancer
October 12th 2017Based on data from the phase III MONARCH 3 trial, a new drug application for abemaciclib (Verzenio) has been granted a priority review by the FDA for use in combination with an aromatase inhibitor for the frontline treatment of women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Read More
Pertuzumab Granted Priority Review by FDA for HER2+ Breast Cancer
September 29th 2017A supplemental biologics license application for pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer has been granted a priority review by the FDA.
Read More
Abemaciclib Approved by FDA for Use in HR+/HER2- Breast Cancer
September 28th 2017Abemaciclib (Verzenio) has been approved by the FDA for use as a monotherapy and in a combination regimen for patients with HR-positive/HER2-negative breast cancer. As a monotherapy, the CDK4/6 inhibitor has been approved for patients with metastatic disease who have previously received endocrine therapy and chemotherapy, and as a combination, abemaciclib has been approved for use with fulvestrant for women with advanced breast cancer with disease progression following endocrine therapy.
Read More
The Optimal Duration of Pertuzumab Treatment for Patients With HER2+ Breast Cancer
September 19th 2017Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses questions still surrounding the optimal duration of pertuzumab (Perjeta) treatment for patients with HER2-positive breast cancer.
Watch